New drug combo aims to boost weight loss in obesity trial

NCT ID NCT06965413

Ongoing Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 12, 2026 · Updated 2 times

Summary

This study tests whether adding an experimental drug (RO7204239) to an existing weight-loss medication (tirzepatide) helps adults with obesity or overweight lose more weight over 48 weeks. About 285 participants without diabetes will receive either the combination or a placebo plus tirzepatide. The goal is to see if the combination is safe and more effective for weight loss.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Obesity obesity disorder Overweight

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OBESITY OVERWEIGHT OVERWEIGHT WITH ONE WEIGHT RELATED COMORBIDITY

Contacts and locations

Locations

Accellacare North London

Northwood, HA6 2RN, United Kingdom
Accellacare Research of Winston Salem

Winston-Salem, North Carolina, 27103, United States
Accellacare South London

Orpington, BR5 3QG, United Kingdom
Accellacare Warwickshire

Coventry, CV3 4FJ, United Kingdom
Accellacare Yorkshire

Shipley, Yorkshire, BD18 3SA, United Kingdom
Accellacare of Bristol/ Internal Medicine & Pediatrics

Bristol, Tennessee, 37620, United States
Accellacare of Duly Health and Care

Oak Lawn, Illinois, 60453, United States
Accellacare of Knoxville

Knoxville, Tennessee, 37912, United States
Accellacare of Piedmont Healthcare

Statesville, North Carolina, 28625, United States
Accellacare of Salisbury

Salisbury, North Carolina, 28144, United States
Accellacare of Wilmington, LLC

Wilmington, North Carolina, 28401, United States
Centrum Medyczne ALL-MED

Krakow, Lesser Poland Voivodeship, 30-033, Poland
Clinical Research Associates

Nashville, Tennessee, 37203, United States
Consano Clinical Research

Shavano Park, Texas, 78231, United States
ETG Warszawa

Warsaw, 02-677, Poland
Ekamed sp. z o.o.

Lublin, 20-718, Poland
Encompass Clinical Research

Spring Valley, California, 91978, United States
Fylde Coast Clinical Research at Layton Medical Centre

Blackpool, Lancashire, FY3 7EN, United Kingdom
Hospital San Rafael A Coruna

A Coruña, LA Coruna, 15006, Spain
Hospital Universitario Vall d'Hebron

Barcelona, 08035, Spain
Hospital Universitario Virgen de la Victoria

Málaga, 29010, Spain
Hospital Vithas Nisa Sevilla

Castilleja de la Cuesta, Granada, 41950, Spain
Instituto De Investigacion Marques De Valdecilla (IDIVAL)

Santander, Cantabria, 39008, Spain
Juno Research, LLC

Houston, Texas, 77040, United States
K2 Medical Research-Winter Garden

Clermont, Florida, 34711, United States
Manassas Clinical Research Center

Manassas, Virginia, 20110, United States
NexGen Research

Lima, Ohio, 45801, United States
Penta Hospials Badania Kliniczne Gdansk

Gdansk, Pomeranian Voivodeship, 80-546, Poland
Pinnacle Research Group

Anniston, Alabama, 36207, United States
Rochester Clinical Research

Rochester, New York, 14609, United States
Rophe Adult and Pediatric Medicine/SKYCRNG

Union City, Georgia, 30291, United States
Texas Diabetes & Endocrinology, P.A.

Austin, Texas, 78731, United States
Universidad de Sevilla - Hospital Universitario Virgen Macarena

Seville, Barcelona, 41009, Spain
University Hospitals of Leicester NHS Trust - Leicester General Hospital (LGH)

Leicester, Leicestershire, LE5 4PW, United Kingdom
Velocity Clinical Research (Impact Research Institute)

Waco, Texas, 76710, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.